ContraFect Stock Price, News & Analysis (NASDAQ:CFRXU)

$6.11 -0.16 (-2.55 %)
(As of 01/16/2018 08:00 AM ET)
Previous Close$6.11
Today's Range$5.75 - $6.60
52-Week Range$5.24 - $7.87
VolumeN/A
Average VolumeN/A
Market Capitalization$117.86 million
P/E Ratio-4.81
Dividend YieldN/A
BetaN/A

About ContraFect (NASDAQ:CFRXU)

ContraFect Corporation (ContraFect ) is a biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. It intends to address drug-resistant infections using its therapeutic product candidates from its lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). Its product candidates are CF-301, a lysin for the treatment of Staph aureus bacteremia, and CF-404, a combination of mAbs for the treatment of life-threatening seasonal and pandemic varieties of influenza. CF-301 and CF-302 are bacteriophage lysins with potent activity against Staph aureus infections.

Receive CFRXU News and Ratings via Email

Sign-up to receive the latest news and ratings for CFRXU and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:CFRXU
CUSIPN/A
Phone+1-914-2072300

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-4.81102362204724
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares24,740,000

ContraFect (NASDAQ:CFRXU) Frequently Asked Questions

What is ContraFect's stock symbol?

ContraFect trades on the NASDAQ under the ticker symbol "CFRXU."

Who are some of ContraFect's key competitors?

Who are ContraFect's key executives?

ContraFect's management team includes the folowing people:

  • Steven C. Gilman Ph.D., Chairman of the Board, Chief Executive Officer (Age 64)
  • Joshua B. Muntner, Co-Chief Executive Officer, Senior Vice President - Business Development (Age 48)
  • Michael Messinger CPA, Co-Chief Executive Officer, Vice President - Finance (Age 42)
  • Roger Pomerantz M.D., Vice Chairman of the Board (Age 60)
  • Nancy Dong, Vice President, Controller
  • Cara M. Cassino M.D., General Counsel, Secretary, Chief Medical Officer (Age 55)
  • Natalie Bogdanos, General Counsel and Corporate secratary (Age 46)
  • Sol J. Barer Ph.D., Lead Independent Director (Age 69)
  • Lisa R. Ricciardi, Director (Age 56)
  • Isaac Blech, Independent Director (Age 67)

How do I buy ContraFect stock?

Shares of ContraFect can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ContraFect's stock price today?

One share of ContraFect stock can currently be purchased for approximately $6.11.

How big of a company is ContraFect?

ContraFect has a market capitalization of $117.86 million.

How can I contact ContraFect?

ContraFect's mailing address is 28 Wells Ave Ste 3, YONKERS, NY 10701-7045, United States. The biotechnology company can be reached via phone at +1-914-2072300.


MarketBeat Community Rating for ContraFect (CFRXU)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  21 (Vote Outperform)
Underperform Votes:  27 (Vote Underperform)
Total Votes:  48
MarketBeat's community ratings are surveys of what our community members think about ContraFect and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ContraFect (NASDAQ:CFRXU) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Earnings History for ContraFect (NASDAQ:CFRXU)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

ContraFect (NASDAQ:CFRXU) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for ContraFect (NASDAQ:CFRXU)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ContraFect (NASDAQ CFRXU)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

ContraFect (NASDAQ CFRXU) News Headlines

Source:

SEC Filings

ContraFect (NASDAQ:CFRXU) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

ContraFect (NASDAQ CFRXU) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.